

Electronic Acknowledgement Receipt

EFS ID:	7130023
Application Number:	09423698
International Application Number:	
Confirmation Number:	7060
Title of Invention:	MULTIVALENT VACCINE COMPOSITION WITH MIXED CARRIER
First Named Inventor/Applicant Name:	ODILE LEROY
Customer Number:	20306
Filer:	Michael S. Greenfield
Filer Authorized By:	
Attorney Docket Number:	99-849-A
Receipt Date:	03-MAR-2010
Filing Date:	10-FEB-2000
Time Stamp:	18:53:29
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$3160
RAM confirmation Number	8804
Deposit Account	132490
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Extension of Time	99-849-A_5mo_EOT.pdf	145526 <small>c559885297d9a642fec153f81780bd153ac35d</small>	no	1
Warnings:					
Information:					
2		99-849-A_ResponseAfterFinal_3-3-10.pdf	3442601 <small>f63c55dc4e499c561a92bba7c5563f2949948fc</small>	yes	29
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment After Final		1	1	
	Amendment Copy Claims/Response to Suggested Claims		2	5	
	Applicant Arguments/Remarks Made in an Amendment		6	26	
	Miscellaneous Incoming Letter		27	29	
Warnings:					
Information:					
3	Rule 130, 131 or 132 Affidavits	99-849-A_Rule132_Schulz_Declaration.pdf	864773 <small>4c3c2c8f18131d15159d71780c0558408765c480a</small>	no	11
Warnings:					
Information:					
4	Foreign Reference	WO03051392.pdf	1746985 <small>68d3ae50c6677244a25c8fa3a3d7d31e02943388b</small>	no	47
Warnings:					
Information:					
5	NPL Documents	Steinhoff_RandomizedComparison_P368_372.pdf	490312 <small>2974baef13c4a8c40d5546c27d889070b49b556a02</small>	no	5
Warnings:					
Information:					

6	NPL Documents	Chiu_SafetyAndImmunogenicity_G71.pdf	83222 e15d8813dc110d142dbd38477b5f9976a7 Re51f	no	1
Warnings:					
Information:					
7	NPL Documents	Daum_Immunogenicity_G65.pdf	89607 a52b8b7431b040c792ad7b0b952529411c 43b4e	no	1
Warnings:					
Information:					
8	NPL Documents	OBrien_ImmunologicPriming.pdf	631945 89b6f92ba543fd58e40b568eca8baf45f8b3 ae50	no	6
Warnings:					
Information:					
9	NPL Documents	Rennels_Abstract1082.pdf	144394 531b7245367b7b18b4015ae15761155ae925 81166	no	1
Warnings:					
Information:					
10	NPL Documents	Shelly_Comparison.pdf	660054 Q79049961b15a0d761834b3d65dacf34897 e034	no	6
Warnings:					
Information:					
11	NPL Documents	Kennedy_G88_P236_ImmunologicResponse.pdf	100213 c19e1049b87e53effc0f56b26d65045330425 7542	no	1
Warnings:					
Information:					
12	NPL Documents	Nieminen_Mucosal.pdf	93149 24c27e4f63a4f1d6f7732c10a2a917b1158e 636d	no	1
Warnings:					
Information:					
13	NPL Documents	Portier_SerumAntibody.pdf	81461 7eae8485297ae0502908f7f4c3b369c708 b3d9	no	1
Warnings:					
Information:					
14	NPL Documents	Keyserling_Immunogenicity.pdf	75456 d4ac218bf3f633cac3d3ba244f85d0515af02 95a	no	1
Warnings:					
Information:					

15	NPL Documents	Kennedy_ImmunologicResponseToLicensed.pdf	44844 ec8f1a417900f191951287176a53e8bc3f1823bb	no	1
Warnings:					
Information:					
16	NPL Documents	Kayhty_Pneumococcal.pdf	522159 288e51d73558c532ee9346a80a9c3f631895a7fa	no	6
Warnings:					
Information:					
17	NPL Documents	Dagan_ReductionOfNasopharyngeal.pdf	741301 e193b526593f6f2b2b26460513ce71cd785864	no	8
Warnings:					
Information:					
18	NPL Documents	Sood_CapsularPolysaccharide.pdf	634618 62a97878f2a6c33be933b5b22ebc496cedf55	no	7
Warnings:					
Information:					
19	NPL Documents	Sarnaik_StudiesOnPneumococcus.pdf	660898 c7fa8db4812314e1ab5507a6b9110da29874e2a79	no	6
Warnings:					
Information:					
20	NPL Documents	Andrew_PneumococcalVaccines.pdf	1244151 2a6d4b5f9b94c9e1145a79ba2f73abb63aefb5414f	no	14
Warnings:					
Information:					
21	NPL Documents	Dagan_ReductionOfPneumococcal.pdf	538901 98b648aa992825f815a4610a7657c0fb3a7e9ca	no	5
Warnings:					
Information:					
22	NPL Documents	Lindberg_Recent_Trends.pdf	819314 fa0651cc6664a5c795c591d3a8fb0b10e99a0d0575	no	13
Warnings:					
Information:					
23	NPL Documents	Greenberg_FactorsInfluencing_P121.pdf	184429 b55c4b6f98637aadb4412a12f2c7b3bc44da89bb8ca	no	2
Warnings:					
Information:					

24	NPL Documents	Ahman_ImmunogenicityOfTetraValent_Abstracts.pdf	158624 37bdf1aaf7e7b28b7647719f0ba4592792f6d99	no	2
Warnings:					
Information:					
25	NPL Documents	Schutze_CarrierInduced_2319_2322.pdf	391774 8c57fb34d394604a680261ac11b9ab7a186935c	no	4
Warnings:					
Information:					
26	NPL Documents	Develasco_MicrobiologicalReviews_P591_603.pdf	1447601 781d384e7251844775113f6e9382b4b78b112c	no	13
Warnings:					
Information:					
27	NPL Documents	Insel_P35_47.pdf	905553 ec5dc03c3be9c8a18e41a3d9000a29750e9fed	no	13
Warnings:					
Information:					
28	NPL Documents	Galelli_P2397_2405.pdf	1039847 c92f1db7727803d2f3b26dc69c26c58a225d73	no	9
Warnings:					
Information:					
29	NPL Documents	Barrington_InfectionAndImmunity_P432_438.pdf	633047 9d4d6568cc0172a4b883c20bc9bdc552c6371aaf	no	7
Warnings:					
Information:					
30	NPL Documents	DiJohn_LancetP1415_1418.pdf	396920 b7a2895a71b11782889960c0518ac480fc6a86a9a	no	4
Warnings:					
Information:					
31	NPL Documents	Leclerc_P1343_1349.pdf	820572 d70ac1759771d3d4443d205a8d9f09277d445	no	7
Warnings:					
Information:					
32	NPL Documents	Clemens_AnnualsNewYorkAcademyOfScience_P255_266.pdf	875688 a4ebc8019c1a6a123a5a7db5d3af24d348793b4e	no	12
Warnings:					
Information:					

33	NPL Documents	Molrine_AnnalsOfInternalMedicine.pdf	745514 e0a0f78205c217bc5348bc7892951d5c1d68d6cf	no	7
Warnings:					
Information:					
34	NPL Documents	Anderson_1554_1559.pdf	418119 31043e4c16333333b0bdc2624670e99da23c69821	no	6
Warnings:					
Information:					
35	NPL Documents	Peeters_MethodsInMolecularMedicine_P111_133.pdf	1719822 d139b14b0b16c99ab271c0a29402edc3bf160887	no	23
Warnings:					
Information:					
36	NPL Documents	Andre_CombinationVaccines_Jan1999.pdf	80121 8216c3690da0bda1867540f7104910af5502b2b	no	2
Warnings:					
Information:					
37	NPL Documents	Anderson_Immunol_P2464_2468.pdf	554691 6973b20972a6e4d00fec095f0eae6773a72ff	no	5
Warnings:					
Information:					
38	NPL Documents	Butler_InfectDis_P885_889.pdf	435628 1e0f15ac20a008d186311efb3c7753295efdb4c	no	5
Warnings:					
Information:					
39	NPL Documents	Dagan_PediatrInfectDis_91_98.pdf	735035 485da0f7213383a278c5873df158c7ed4861a	no	8
Warnings:					
Information:					
40	NPL Documents	Ellis_Granoff_DevelopmentAndClinicalUses.pdf	357202 51b546d876c4c0a090c008f783ff3aa091f000	no	7
Warnings:					
Information:					
41	NPL Documents	Eskola_Lancet_P1688_1692.pdf	467741 6ef6a0423da6c2a364934e1e13a670b0678134	no	5
Warnings:					
Information:					

42	NPL Documents	Todar_OnlineTextbook.pdf	1401315 b7b17ae684d8a761628aefb0ec29bfe917	no	18
Warnings:					
Information:					
43	NPL Documents	Svenson_Lindberg_ImmunolMeth_P323-335.pdf	875978 c7f341ad9abec805a5aef1c20734dc04f6d1	no	13
Warnings:					
Information:					
44	NPL Documents	Svenson_Lindberg_P490_496.pdf	534599 d8b4888d57efc3e7eb7288d218d243bde1ca8	no	7
Warnings:					
Information:					
45	NPL Documents	Wuorimaa_InfectDis_P1211_1215.pdf	353590 9c08cd81cb781b5c6ef18003411e1ed7d3aeb7abef	no	5
Warnings:					
Information:					
46	NPL Documents	Wuorimaa_Vaccine_P5328_5332.pdf	402888 ed1c3be0472b5286a23fcd36e95d789f12a30f	no	5
Warnings:					
Information:					
47	NPL Documents	Schneerson_InfectImmun_P582_591.pdf	1071210 2cc421cd70926a06dc316285501587a42e1b98ba	no	11
Warnings:					
Information:					
48	NPL Documents	Cho_1995_ICAAC_172.pdf	56176 818e129dab724b3d3d6196a031742c293ef24826	no	1
Warnings:					
Information:					
49	NPL Documents	Kuo_Infirmm_P2706_2713.pdf	881695 0d90aa7e73ba6503c3dffc806c5b881eacdc4dc1	no	8
Warnings:					
Information:					
50	NPL Documents	Eby_Pneumococcal_Conjugate_s_P119_123.pdf	350870 011b4d9557516c30084d6133900b158f8b127c	no	5
Warnings:					
Information:					

51	NPL Documents	Lindberg_PolysaccharideVaccine_s_P69_85.pdf	1128386 8f621b1991b4d62f3db6881b43d6d22609a897b	no	17
Warnings:					
Information:					
52	Miscellaneous Incoming Letter	99-849-A_Transmittal.pdf	305168 29a5c7b072a2d1018b-a807b54eb8249c7f9c88ab	no	2
Warnings:					
Information:					
53	Request for Continued Examination (RCE)	99-849-A_RCE.pdf	922960 d7e18b66c8d8c6f1a5608317e843dc33d06	no	3
Warnings:					
Information:					
54		99-849-A_Suppl_IDS-1.pdf	5821216 944c8ba901ef1275a5e6d128810400501b26217	yes	8
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Information Disclosure Statement (IDS) Filed (SB/08)		1	6	
	Miscellaneous Incoming Letter		7	8	
Warnings:					
Information:					
55	Fee Worksheet (PTO-875)	fee-info.pdf	32666 6050f88f7751795a3917dc88c3ac8f7324319	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			40362529		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.